Company Analysis
Sign in

Moleculin Biotech, Inc. (MBRX)

Nasdaq: MBRX · Pharmaceutical Preparations · Houston, TX · filing with the SEC since 2015
Full chart Alerts Compare
Grade5.1
◀ Past 6.3● Present 4.8▶ Future 4.5
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of Moleculin Biotech, Inc.

Nine metrics read from its own filings, by tense
Headline grade
5.1/10
◀ Past6.325% of the headline
● Present4.835% of the headline
▶ Future4.540% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 4 read as filed from the record and 5 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

6.3/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
2.1/10

Has it survived what it has been through?

12 warning events since 2017; the latest 2026-09-18.

weight 22% of this tense · 21st percentile among 497 sector filers · read for itself

From the record

Moleculin Biotech, Inc.'s filings since 2017 show 12 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 9 times, the latest 2026-09-18); an auditor change (8-K item 4.01, the latest 2017-02-23); a late-report notice (Form NT 10-K or NT 10-Q, 2 times, the latest 2019-08-14) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
5.8/10

What has it actually done, year after year?

9 filed years; profitable in 0 of 9.

weight 45% of this tense · 59th percentile among 323 sector filers · read for its customers

From the record

Moleculin Biotech, Inc.'s 9 filed years say what it did: it never fell from a peak; net income was positive in 0 of 9 of those years (its annual reports).

What it rests on

  • the share of filed years with a profitbottom 27% of its family
  • the deepest fall from a revenue peak0.0%top 10% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
9.8/10

How has it treated the people who own it?

SI estimate 9.8/10, confidence 35 of 100 (one part).

weight 33% of this tense · 98th percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the top 2% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Moleculin Biotech, Inc.'s shareholder treatment is put at 9.8 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 2% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

4.8/1035% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed
2.4/10

Is it financially healthy right now?

ROE -224%: lost 224¢ per shareholder dollar. Leverage 32%: owes 32¢ per asset dollar.

weight 45% of this tense · 24th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Moleculin Biotech, Inc. lost about 224 cents for every dollar of shareholders' money. Leverage: it owed about 32 cents per dollar of assets, and net share issuance: its share count grew 760.1% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetstop 49% of its family
  • return on equitybottom 13% of its family
  • the share count against the year beforebottom 7% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

SI estimate
5.2/10

How strong is its position in its industry?

SI estimate 5.2/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 315 sector filers · read for its customers

SI estimate Inferred, not read as filed

Why it is an estimate
No filed revenue on file, so the desk assumes the typical reading of its industry family, the median of 315 members with one.
What the record cannot read
No filed revenue on file.
How it was reasoned
family median, 315 readings behind it.
Confidence
20 of 100
What would change it
Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Moleculin Biotech, Inc.'s industry position is put at 5.2 of 10 with a confidence of 20 of 100, because no filed revenue on file, so the desk assumes the typical reading of its industry family, the median of 315 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

Leadership

as filed
7.9/10

What are the people in charge doing?

top 21% of 315 in its family for leadership; chief executive since 2016.

weight 33% of this tense · 79th percentile among 315 sector filers · read for its shareholders

From the record

Moleculin Biotech, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Klemp, Walter V (CEO and President, as filed), filing under that title since 2016-06-07, 10.4 years (top 16% of its family); the 8 officers and directors filing in the last fifteen months have been on the record a median of 10.2 years (top 7%); 3 officer or director changes were reported on Form 8-K since 2023-11-13, against the 8 people in charge now (top 39%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

  • officer and director changes on Form 8-K, against the people in charge3 in three years among 8 peopletop 39% of its family
  • the median years the people in charge have filed10.2 yearstop 7% of its family
  • the chief executive's years on the record10.4 yearstop 16% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

4.5/1040% of the headline grade · 0 of 3 filed, 3 estimated

Room to expand

SI estimate
6.1/10

How much room does it have to grow?

SI estimate 6.1/10, confidence 35 of 100 (one part).

weight 33% of this tense · 61st percentile among 479 sector filers · read for itself

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, cash less debt against assets, which ranks in the top 39% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
What the record cannot read
The record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
How it was reasoned
one part: cash less debt against assets, the one part on file, ranked among 479 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Moleculin Biotech, Inc.'s room to expand is put at 6.1 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the top 39% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.

Growth drivers

SI estimate
3.9/10

What could actually drive growth from here?

SI estimate 3.9/10, confidence 35 of 100 (one part).

weight 45% of this tense · 39th percentile among 323 sector filers · read for its customers

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the three-year growth of research spending, which ranks in the bottom 39% of 323 in its family; the record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending.
What the record cannot read
The record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending.
How it was reasoned
one part: three-year growth of research spending, the one part on file, ranked among 323 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Moleculin Biotech, Inc.'s growth drivers is put at 3.9 of 10 with a confidence of 35 of 100, because read from one part only, the three-year growth of research spending, which ranks in the bottom 39% of 323 in its family; the record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending. A filing that carries the missing parts replaces this estimate with the filed reading.

Expectations vs reality

SI estimate
3.4/10

Did its newest year beat what its own record pointed to?

SI estimate 3.4/10, confidence 35 of 100 (one part).

weight 22% of this tense · 34th percentile among 284 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, net income against the prior three years' average, which ranks in the bottom 34% of 284 in its family; the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
What the record cannot read
The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned
one part: net income against the prior three years' average, the one part on file, ranked among 284 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Moleculin Biotech, Inc.'s expectations vs reality is put at 3.4 of 10 with a confidence of 35 of 100, because read from one part only, net income against the prior three years' average, which ranks in the bottom 34% of 284 in its family; the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change. A filing that carries the missing parts replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton MBRX · research, not advice